Results for
""Simendan""[mesh_terms]

Ca2+-sensitisers--a promising option to treat heart failure?

Robert H G Schwinger, Heike Katharina Hoyer, Klara Brixius

Cardiovascular drugs and therapy 2007;19(6):423-8

Levosimendan in paediatric cardiac anaesthesiology: A systematic review and meta-analysis.

Steffen Rex, Filip Rega, Matthias Lapere

European journal of anaesthesiology 2022;39(8):646-655

Reducing perioperative myocardial infarction with anesthetic drugs and techniques.

G Landoni, M Zambon, A Zangrillo

Current drug targets 2009;10(9):858-62

The importance of pharmacokinetics, pharmacodynamic and repetitive use of levosimendan.

Joanna Banach, Małgorzata Dobosiewicz, Wojciech Hertmanowski, Mirosława Kowalkowska, Wojciech Gilewski, Daniel Rogowicz, Łukasz Wołowiec, Grzegorz Grześk

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2022;153():113391

Levosimendan in the treatment of patients with acute cardiac conditions: an expert opinion of the Association of Intensive Cardiac Care of the Polish Cardiac Society.

Grzegorz Grześk, Rafał Depukat, Marek Deja, Jarosław Bugajski, Marek Gierlotka, Agnieszka Tycińska, Marcin Gruchała, Jarosław D Kasprzak, Janina Stępińska, Robert Zymliński, Barbara Zawiślak, Katarzyna Wilk, Ewa Straburzyńska-Migaj, Bożena Sobkowicz, Joanna Płonka, Przemysław Leszek, Ewa Kucewicz-Czech, Jacek Kubica

Kardiologia polska 2021;78(7-8):825-834

Effect of levosimendan in patients with acute decompensated heart failure : A meta-analysis.

S Zhou, J Li, L Zhang

Herz 2019;44(7):630-636

Use of Levosimendan in Patients with Pulmonary Hypertension: What is the Current Evidence?

Giuseppe Pacileo, Ryan J Tedford, Piero Pollesello, Michelle Kittleson, Daniele Masarone

Drugs 2023;83(3):195-201

Calcium sensitizer agents: a new class of inotropic agents in the treatment of decompensated heart failure.

Edgardo J Kaplinsky, Sergio V Perrone

International journal of cardiology 2005;103(3):248-55

Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial.

Ammar Al-Chalabi, Chris Garratt, Merit Cudkowicz, Mikko Kuoppamäki, Toni Sarapohja, Valtteri V Aho, Leonard van den Berg, Susanne Petri, Nicholas Maragakis, Angela Genge

The Lancet. Neurology 2021;20(10):821-831

Comparative Efficacy of Levosimendan, Ramipril, and Sacubitril/ Valsartan in Isoproterenol-induced Experimental Heart Failure: A Hemodynamic and Molecular Approach.

Fauzia Tabassum, Asif Ansari Shaik Mohammad, Arun Kumar Sharma, Mohd Zaheen Hassan, Abdulmalik Altamimi, Obaid Afzal, Quamrul Hassan, Md Sayeed Akhtar

Current molecular pharmacology 2023;16(6):629-639

Levosimendan: a parenteral calcium-sensitising drug with additional vasodilatory properties.

L A Lehtonen

Expert opinion on investigational drugs 2001;10(5):955-70

Levosimendan: mechanistic insight and its diverse future aspects in cardiac care.

Md Sayeed Akhtar, Fauzia Tabassum, Arun Kumar Sharma, Mohamed Jawed Ahsan, Mallika Khurana, Syed Obaidur Rahman, Abdulmalik S A Altamimi, Obaid Afzal, Sirajudeen S Alavudeen, Aisha Siddiqui, Md Quamrul Hassan

Acta cardiologica 2023;78(2):170-187

Advanced heart failure: an appraisal of the potential of levosimendan in this end-stage scenario and some related ethical considerations.

Friedrich Fruhwald, Piero Pollesello, Sonja Fruhwald

Expert review of cardiovascular therapy 2017;14(12):1335-1347

Levosimendan: a new approach for the treatment of patients with severe heart failure. A brief summary based on a clinical case.

Nuno Pontes, Berta Dias, João Morais

Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology 2003;22(7-8):941-8